Martindale Pharma to launch Prenoxad Injection in five more EU countries

Martindale Pharma's Prenoxad Injection therapy has received regulatory approval in Sweden, Denmark, Ireland, Finland and Estonia.

The world's first take-home naloxone product, Prenoxad Injection is designed specifically for use by non-healthcare professionals to treat opioid overdoses in a community setting. Since its UK launch, more than 85,000 units or kits have been supplied.

This new approval will help the company bring the treatment to a greater number of the approximately 1.3 million people in Europe who suffer from opioid addiction, with systematic reviews having shown that take-home naloxone programmes can prevent overdose fatalities.

Michael Harris, chief executive officer of Martindale Pharma, said: "Prenoxad Injection has already been shown to reduce opioid overdose deaths when offered as part of a harm reduction programme in the UK, and this important regulatory step will help that goal be achieved in many more countries."

Additionally, Martindale Pharma has announced the out-licensing of exclusive commercial rights to Prenoxad Injection for France to Ethypharm, a specialty pharmaceutical company focused on pain and addiction.